AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02471651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal anti-VEGF injection
Description: This injection may be ranibizumab, bevacizumab, or aflibercept.
Study NCT05019248 — intervention group
Intervention type: BIOLOGICAL
Intervention: Most recent vaccine to seasonal influenza
Description: Seasonal Influenza vaccine: according to the latest SmPC and according to national guidelines (published by the Standing Committee on Vaccination (STIKO)).
Study NCT02616874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVA.HIVconsv vaccine
Description: Dose: 2x10e8 pfu, Interval: weeks 0 and 9.
Study NCT02616874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Dose: 5mg/m2 over 4hours, Interval: weeks 3, 4 and 5
Study NCT02251327 — intervention group
Intervention type: DEVICE
Intervention: Investigational Xpert DST test
Description: One investigational test performed directly on the same sputum specimen.
Study NCT04824482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot-assisted treadmill gait training (RTGT)
Description: Locomotor training guided by the robotic device (Lokomat Hocoma) according to a pre-programmed gait pattern with the help of robot-driven exoskeleton orthoses. The process of gait training is automated and controlled by a computer under supervision of a physiotherapist.
Study NCT04824482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapist-assisted treadmill gait training (TTGT)
Description: Locomotor training via a repetitive execution of walking movements manually guided by a physiotherapist during treadmill gait training.
Study NCT04419948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White bread
Description: White bread (120g) containing 54 g CHO
Study NCT04419948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Butter
Description: Butter 39 g
Study NCT04419948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined olive oil
Description: Refined olive oil (40 ml).
Study NCT04419948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EVOO with 250 mg/kg oleocanthal
Description: Extra virgin olive oil containing 250 mg/kg oleocanthal.
Study NCT04419948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EVOO with 500 mg/kg oleocanthal
Description: Extra virgin olive oil containing 500 mg/kg oleocanthal.
Study NCT04419948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 400 mg
Study NCT04072510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-esteem group
Description: The intervention will comprise of 6 sessions of group self-esteem therapy which uses a cognitive behavioural approach. The therapy has been manualised into a 76 page treatment protocol and will be administered by Assistant Psychologists employed at Newbridge House receiving weekly supervision from a Clinical Psychologist. The self-esteem group is based on Melanie Fennel's cognitive behavioural model of low self-esteem addressing thoughts, feeling and behaviours. The group aims to improve self-esteem and build positivity.~The sessions are structured and laid out in the following overview:~Week 1, Session 1: What is self-esteem and an introduction to CBT Week 2, Session 2: How might low self-esteem develop? Week 3, Session 3: Negative automatic thoughts Week 4, Session 4: Challenging negative automatic thoughts Week 5, Session 5: Creating new coping strategies Week 6, Session 6: Building positivity
Study NCT04072510 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist.
Study NCT04477928 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sera and whole blood sampling
Description: * Study Entry: Single Nucleotide Polymorphism (SNP)-Based Genetic Risk Score at study entry.~* 2 years old: T1D autoantibodies, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibodies~* 5 years old: T1D and celiac autoantibodies~* 9-16 year old: one-time T1D and celiac autoantibodies~* Siblings of people with T1D autoimmunity, ages 6-17 years: one-time T1D and celiac autoantibodies
Study NCT04477928 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Differential Gene Expression (DGE)
Description: Opt-in: Differential Gene Expression from cord blood at birth and peripheral blood at 12 months of age
Study NCT02055131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aspirin
Study NCT04437940 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vaginal fluid Covid-19 PCR test
Description: Vaginal fluid samples are tested for Covid-19
Study NCT04405518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrinogen Concentrate (Human) 1 MG [RiaSTAP]
Description: The drug used in this study is Riastap, 1g (Fibrinogen). The dose administered will depend on the arm group assigned and in the results of the thromboelastogram during the procedure.
Study NCT04405518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen Concentrate (Human) 1 MG [RiaSTAP]
Description: The drug used in this study is Riastap, 1g (Fibrinogen). The dose administered will depend on the arm group assigned and in the results of the thromboelastogram during the procedure.
Study NCT03407794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented vegetable
Description: The intervention is to consume 1/2 cup fermented vegetables every day for 6 weeks
Study NCT03407794 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-fermented vegetable
Description: The intervention is to consume 1/2 cup of non-fermented vegetables every day for 6 weeks
Study NCT04719689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Experimental group 1 got this intervention containing Dry needling for 10 mins, followed by conventional physiotherapy treatment (hot pack and stretching) for 15 mins. Participants were treated 6 times over a 3 week period with 2 treatment sessions per week per patient. Pre and Post treatment readings were taken in 1st and 6th session over a 3 week period respectively. A follow up reading was also taken after 1 month for checking prolonged post treatment effects. Assessment was done via Pressure pain threshold Scale, Pelvic goniometer and Measuring tape for assessing functional positional fault of pelvis and muscle length of Quadratus lumborum
Study NCT04719689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry cupping
Description: Experimental group 2 got this intervention containing Dry cupping for 10 mins, followed by conventional physiotherapy treatment (hot pack and stretching) for 15 mins. Participants were treated 6 times over a 3 week period with 2 treatment sessions per week per patient. Pre and Post treatment readings were taken in 1st and 6th session over a 3 week period respectively. A follow up reading was also taken after 1 month for checking prolonged post treatment effects. Assessment was done via Pressure pain threshold Scale, Pelvic goniometer and Measuring tape for assessing functional positional fault of pelvis and muscle length of Quadratus Lumborum
Study NCT02771743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT02771743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study NCT02771743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT02771743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02771743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Study NCT02771743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT02771743 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tandem HDCT/auto-SCT
Study NCT03588390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to high strength tablet
Study NCT02771743 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study NCT02771743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Study NCT02771743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Study NCT02771743 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MIBG
Study NCT03439774 — intervention group
Intervention type: DEVICE
Intervention: Topcon CT-800
Description: tonometer
Study NCT03439774 — intervention group
Intervention type: DEVICE
Intervention: Topcon TRK-2P
Description: tonometer, pachymeter
Study NCT01165775 — intervention group
Intervention type: DEVICE
Intervention: Dexcom Seven Plus Continuous Glucose Monitoring System
Description: Soft sensor for continuous glucose monitoring inserted for up to 24 hours prior to administration of betamethasone. Device to be worn for duration of hospitalization or up to 7 days total, whichever time period is shorter.
Study NCT03577587 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Silitidil for 21 days
Description: daily ingestion of herbal galactagogue Silitidil over time period of 3 weeks
Study NCT01502787 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm blood flow
Description: Using high-resolution ultrasound, investigators will measure skeletal muscle blood flow in the forearm at rest, following handgrip exercise (described below), and following Angiotensin II infusion (described below).
Study NCT01502787 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microneurography
Description: Investigators will measure sympathetic nerve activity from the peroneal nerve by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. With this stimulation, subject will notice either involuntary twitching or a tingling sensation, which may be annoying but not painful. Investigators will then introduce a tiny, sterile wire needle (an electrode) through the skin at the same location. When the tip of the needle enters the nerve, subjects may again notice involuntary muscle twitches or tingling in the leg. Investigators will then turn the electrical stimulator off and make minor adjustments in the position of the needle until investigators begin to record the nerve signals. The recording needle will remain in position throughout the study.
Study NCT01502787 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rhythmic handgrip exercise
Description: Subjects will perform a rhythmic handgrip exercise at 30% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise.
Study NCT01502787 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lower body negative pressure
Description: Lower body negative pressure increases sympathetic nerve activity. Therefore, investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure and sympathetic nerve activity at baseline and after rhythmic handgrip exercise plus lower body negative pressure (LBNP) for 2 minutes.
Study NCT01502787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin II
Description: Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure and sympathetic nerve activity at baseline and during intravenous infusion of Angiotensin II at the dose of 1, 2, and 3 ng/kg/min for 15 minutes at each dose.
Study NCT02652299 — intervention group
Intervention type: BIOLOGICAL
Intervention: Synovial biopsy
Description: Synovial tissue for analysis and biobank.
Study NCT01631318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced ultrasound imaging
Description: Ultrasound imaging procedure
Study NCT01631318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Tracking Device
Description: Optical Tracking Device, manufactured by Atracsys LLC, Switzerland.
Study NCT01631318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic Tracking Device
Description: Electromagnetic Tracking Device, Ascension Technology Corporation, Milton, Vermont.
Study NCT01631318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren
Description: Perflutren lipid microsphere, IV 0.4 mL. Used as standard contrast agent, not the subject of the study.
Study NCT04723784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Initial Assessment
Description: In this phase the evaluation of the participants will be done, with the application of the instrument presented in outcome measures' section. According to the age of the person, specific questionnaires will be used to gather information more concrete about the skills for mobility. This assessment will allow determining the specific needs, demands and capabilities of participants. The assessment process will be done by professionals of research groups in rooms of collaborators centers.
Study NCT04723784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of assistive technology in the daily life of participants
Description: The professionals of collaborator centers, supported by the research groups, will carry on the training in the use of AT by the participants, facilitating its incorporation during the performance of activities of daily living.
Study NCT04723784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of outcome measures
Description: After the process of implementation of AT (the next 2 and 6 months), members of the research group and the professionals of collaborators centers will apply the measurement instruments to determine the possible improvements in the level of functional independence (FIM scale) of people with disabilities, the impact that the AT has had on their lifes (PIADS scale) and the level of matching between person and AT (ATD PA - MPT model).
Study NCT00572299 — intervention group
Intervention type: DRUG
Intervention: alendronate
Description: 70 mg of alendronate orally per week for at least three months in patients receiving at least 10 mg/day or oral prednisone for at least three months
Study NCT00443755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: To minimize side effects the metformin will be initiated at 500 mg twice daily with meals and increased to 1 gm twice daily with meals after two weeks and continue to a total of 3 months of dosing.
Study NCT00443755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: To minimize side effects, the pioglitazone will be initiated at 30 mg daily and increased to 45 mg daily after two weeks, and continue to a total of 3 months of dosing.
Study NCT00443755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching the metformin and pioglitazone tablets are given in the same regimen as the active drug arm for 3 months.
Study NCT01937364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: Baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
Study NCT01937364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical appearing placebo every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
Study NCT03309800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL301
Description: HL301: 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
Study NCT03309800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HL301(Placebo)
Description: HL301(Placebo): 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
Study NCT00658320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 0.75 mg twice daily, trough level adjusting between 3 and 8 ng/ml.
Study NCT00658320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Description: The initial dose of 2 gm/day Mycophenolate mofetil was started within 24-36 hours from reperfusion after transplantation. MMF was administered daily for 12 months in the core study and 12 months in the extension study.
Study NCT00658320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Patients received first dose of basiliximab (20 mg) 2 hours prior to transplantation and 20 mg at Day 4 or according to local practice
Study NCT00658320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: Patients received first dose of basiliximab (20 mg) 2 hours prior to transplantation and 20 mg at Day 4 or according to local practice
Study NCT00658320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: The cyclosporine was initiated either pre-transplant or within 24 hours after transplantation following local regime. Standard dose of cyclosporine was administered with MMF. The Reduced dose of cyclosporine was administered with everolimus.
Study NCT00658320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine A
Description: The cyclosporine was initiated either pre-transplant or within 24 hours after transplantation following local regime. Standard dose of cyclosporine was administered with MMF. The Reduced dose of cyclosporine was administered with everolimus.
Study NCT00658320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Corticosteroid was administered according to local practice during the trial but at a dose not less than 5mg per day for 12 months of the study
Study NCT00658320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Corticosteroid was administered according to local practice during the trial but at a dose not less than 5mg per day for 12 months of the study
Study NCT02040428 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EVARREST™ Fibrin Sealant Patch
Study NCT02040428 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Topical hemostat
Study NCT01393990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2228820
Description: Administered orally
Study NCT01393990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study NCT01393990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Study NCT00793728 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve gastrectomy
Description: Perform a gastrectomy guided by a 38F catheter and parallel to the small curvature of the stomach
Study NCT00993616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat
Description: Given IV
Study NCT00993616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT02660190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hexaminoavolunate
Study NCT02660190 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WL cystoscopy
Study NCT00312000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine-irinotecan
Description: 1. st line capecitabine 1250 mg/m2 orally b.i.d. on day 1-14~2. nd line q 3 w irinotecan 350 mg/m2 IV infusion on day 1
Study NCT00312000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine+irinotecan (1st line)
Description: q 3 w irinotecan 250 mg/m2 IV infusion in 30 minutes on day 1 2 hours after discontinuation of the infusion followed by capecitabine 1000 mg/m2 orally b.i.d. on day 1-14
Study NCT02702557 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Elastic Band Exercises
Study NCT04003831 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Device: P200TxE
Description: The P200TxE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
Study NCT02317276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone 0.1%
Description: Topical ointment
Study NCT02782117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luminopia One
Description: Luminopia One is a digital therapeutic that allows patients to watch videos with therapeutic modifications applied.
Study NCT00389532 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)
Description: Influenza vaccine
Study NCT00627718 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HRT screening for macula edema
Description: HRT screening for macula edema at time of initial diagnosis of macular degeneration
Study NCT04144296 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Study procedure
Description: * Measurement of the flow rate of supplemental oxygen~* Measurement of the peripheral arterial saturation (SpO2) by pulse oximetry~* Taking of an ABG sample (ABG1) from the arterial line~* Taking of capillary blood gas analysis from the earlobe and from the finger tip~* Taking of an a second ABG (ABG2) from the arterial line
Study NCT04457869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F520
Description: 3mg/kg every 3 weeks
Study NCT02035137 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 131I-MIBG
Study NCT02035137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Study NCT03577587 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for 21 days
Description: daily ingestion of Placebo preparation over time period of 3 weeks
Study NCT02035137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan